PMID- 21095451
OWN - NLM
STAT- MEDLINE
DCOM- 20110315
LR  - 20220330
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 42
IP  - 9 Suppl
DP  - 2010 Nov
TI  - Regression of left ventricular hypertrophy in kidney transplant recipients: the 
      potential role for inhibition of mammalian target of rapamycin.
PG  - S41-3
LID - 10.1016/j.transproceed.2010.07.007 [doi]
AB  - Left ventricular hypertrophy (LVH) contributes to elevated cardiac mortality with 
      graft function in renal transplant recipients. Antihypertensive therapy, and 
      especially angiotensin-converting enzyme (ACE) inhibitors, proved to be effective 
      in regressing the LVH of renal transplant recipients, at least in part by 
      interacting with immunosuppressive agents, thus raising the possibility that 
      immunosuppressive therapy might affect changes in the left ventricular mass (LVM) 
      of recipients. This review mainly focuses on the potential role of mammalian 
      target of rapamycin (mTOR) inhibition to regress cardiac hypertrophy in both 
      experimental models and in the clinical setting. We comment on the results of 
      experimental studies conducted on animal models, which showed regression of 
      cardiac hypertrophy by sirolimus (SRL). We also discuss clinical studies that 
      show that conversion from calcineurin inhibitors to SRL is effective to achieve 
      regression of LVH in both kidney and cardiac transplant recipients, mainly by 
      reducing the true left ventricular wall hypertrophy.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Paoletti, E
AU  - Paoletti E
AD  - Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria 
      San Martino, Genova, Italy. ernesto.paoletti@hsanmartino.it
FAU - Cannella, G
AU  - Cannella G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Calcineurin Inhibitors)
RN  - 0 (Immunosuppressive Agents)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antihypertensive Agents/therapeutic use
MH  - Calcineurin Inhibitors
MH  - Disease Models, Animal
MH  - Humans
MH  - Hypertrophy, Left Ventricular/*drug therapy/enzymology/pathology
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kidney Transplantation/*adverse effects
MH  - Sirolimus/*therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Treatment Outcome
EDAT- 2010/12/09 06:00
MHDA- 2011/03/16 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/12/09 06:00 [pubmed]
PHST- 2011/03/16 06:00 [medline]
AID - S0041-1345(10)01052-3 [pii]
AID - 10.1016/j.transproceed.2010.07.007 [doi]
PST - ppublish
SO  - Transplant Proc. 2010 Nov;42(9 Suppl):S41-3. doi: 
      10.1016/j.transproceed.2010.07.007.